Advertisement GE Healthcare launches new bioprocess affinity resin - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

GE Healthcare launches new bioprocess affinity resin

GE Healthcare and BAC, a provider of antibody-based affinity purification technology, have launched new bioprocess affinity resin, LambdaFabSelect.

The new resin is a designed tool for the GMP-regulated purification of antibodies and antibody fragments that contain a lambda light chain.

GE Healthcare Life Sciences custom design media director Henrik Ihre said collaborating with the team at BAC has resulted in a ready-to-use product for all human antibody formats containing a lambda light chain.

BAC CEO Laurens Sierkstra said LambdaFabSelect enables bioprocess engineers to use BAC’s ligand technology to produce Fab fragments with a lambda light chain for clinical and commercial use.

"It provides greater flexibility in the purification of these important biotherapeutics," added Sierkstra.